Fexofenadine – a literature review focused on efficacy and safety Review article

Article Sidebar

PDF (Język Polski)


Published: Nov 22, 2021
DOI: https://doi.org/10.24292/01.AP.174221121
Keywords:
fexofenadine, efficacy, safety, allergic rhinitis, urticaria

Main Article Content

Adam J. Sybilski
1. II Klinika Pediatrii, Centrum Medyczne Kształcenia Podyplomowego w Warszawie. 2. Klinika Chorób Dziecięcych i Noworodkowych z Centrum Alergologii i Dermatologii, Centralny Szpital Kliniczny MSWiA w Warszawie
http://orcid.org/0000-0003-2389-277X

Abstract

The first-line drugs in allergic rhinitis (seasonal and perennial) and chronic urticaria are H1 receptor blockers (antihistamines). One of the better known and tested new generation antihistamines is fexofenadine. It is an oral, long-acting, bipolar, non-sedative, inverse agonist of the H1 receptor (binds to the same part of the receptor as the agonist but produces the opposite effect), with affinity for G protein-coupled histamine receptors. Fexofenadine is minimally metabolized in the liver and is excreted mainly in the stool after its active transport to the intestine. The clinical efficacy (improvement in the severity of the symptoms of allergic rhinitis and urticaria) of fexofenadine was assessed in multicenter studies that showed its antihistaminic, antiallergic and anti-inflammatory effects. Fexofenadine significantly more inhibited the occurrence of wheal and histamine- -induced erythema compared to placebo and I generation drugs. Numerous studies have shown that fexofenadine is a safe drug that does not cause sedation, cardiovascular complications, and the side effects (mainly diarrhea) are mild and quickly disappear.

Downloads

Download data is not yet available.

Article Details

How to Cite
Sybilski , A. J. (2021). Fexofenadine – a literature review focused on efficacy and safety. Alergoprofil, 17(4), 24-30. https://doi.org/10.24292/01.AP.174221121
Issue
Vol 17 No 4 (2021)
Section
THERAPY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Samoliński B, Raciborski F, Lipiec A et al. Epidemiologia Chorób Alergicznych w Polsce (ECAP). Alergol Pol. – Polish J Alergol. 2014; 1: 10-8.
2. Raciborski F, Kłak A, Czarnecka-Operacz M et al. Epidemiology of urticaria in Poland – nationally representative survey results. Adv Dermatol Allergol. 2018; XXXV(1): 67-73.
3. Linneberg A, Dam Petersen K, Hahn-Pedersen J et al. Burden of allergic respiratory disease: a systematic review. Clin Mol Allergy. 2016; 14: 12.
4. Meltzer EO. Allergic Rhinitis: Burden of Illness, Quality of Life, Comorbidities, and Control. Immunol Allergy Clin North Am. 2016; 36: 235-48.
5. Romano M, James S, Farrington E et al. The impact of perennial allergic rhinitis with/without allergic asthma on sleep, work and activity level. Allergy Asthma Clin Immunol. 2019; 15: 81.
6. Bousquet J, Schünemann HJ, Togias A et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Allergic Rhinitis and Its Impact on Asthma Working Group. J Allergy Clin Immunol. 2020; 145(1): 70-80.e3.
7. Scadding GK, Hellings PW, Bachert C et al. Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement. World Allergy Organ J. 2020; 13(5): 100124.
8. Scadding GK, Smith PK, Blaiss M et al. Allergic Rhinitis in Childhood and the New EUFOREA Algorithm. Front Allergy. 2021; 2: 706589.
9. Meltzer EO, Rosario NA, Van Bever H et al. Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis. Allergy Asthma Clin Immunol. 2021; 17: 113.
10. Samoliński B, Krzych-Fałta E, Piekarska B et al. ARIA 2019 – zintegrowana opieka w alergicznym nieżycie nosa – Polska. Alergol Pol. – Polish J Alergol. 2019; 6(4): 111-26.
11. Dressler C, Rosumeck S, Werner RN et al. Executive summary of the methods report for ‘The EAACI/GA 2 LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update’. Allergy. 2018; 73(5): 1145-6.
12. Zuberbier T, Aberer W, Asero R et al. Wytyczne eAAcI/GA-2Len/eDF/WAO dotyczące definicji, klasyfikacji, diagnostyki i leczenia pokrzywki. Alergol Pol. – Polish J Alergol. 2020; 7(1): 1-28.
13. Huang CZ, Jiang ZH, Wang J et al. Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019; 20(1): 72.
14. Sybilski AJ. Feksofenadyna skuteczny i bezpieczny lek w alergicznym nieżycie nosa oraz pokrzywce. Medycyna Faktów. 2017; 4(3): 35-6.
15. Sybilski AJ. Feksofenadyna – fakty mówią same za siebie. Medycyna Faktów. 2019; 3(44): 238-41.
16. Akamine Y, Miura M. An update on the clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol. 2018; 14(4): 429-34.
17. ChPL, Allertec Fexo, 120 mg. https://polpharma.pl/wp-content/uploads/2021/01/221949_.pdf (access: 12.11.2021).
18. Compalati E, Baena-Cagnani R, Penagos M et al. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo controlled clinical trials. Int Arch Allergy Immunol. 2011; 156(1): 1-15.
19. Church MK, Maurer M. H1‐antihistamines and urticaria: how can we predict the best drug for our patient? Clin Exp Allergy. 2012; 42(10): 1423-9.
20. Schoepke N, Church MK, Maurer M. The Inhibition by Levocetirizine and Fexofenadine of the Histamine induced Wheal and Flare Response in Healthy Caucasian and Japanese Volunteers. Acta Derm Venereol. 2013; 93: 286-93.
21. KC S, Aryal A, Adhikary M et al. Comparative Efficacy of Fexofenadine Versus Levocetrizine Versus Desloratadine via 1% Histamine Wheal Suppression Test. Kathmandu Univ Med J. 2020; 69(1): 19-22.
22. Iriarte Sotés P, Armisén M, Usero-Bárcena T et al. Efficacy and Safety of Up-dosing Antihistamines in Chronic Spontaneous Urticaria: A Systematic Review of the Literature. J Investig Allergol Clin Immunol. 2021; 31(4): 282-91.
23. Ring J, Hein R, Gauger A et al. Desloratadine Study Group. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double‐blind, placebo‐controlled study. Int J Dermatol. 2001; 40(1): 72-6.
24. Compalati E, Baena-Cagnani R, Penagos M. et al. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo- controlled clinical trials. Int Arch Allergy Immunol. 2011; 156(1): 1-15.
25. Hampel FC, Kittner B, van Bavel JH. Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis. Ann Allergy Asthma Immunol. 2007; 99(6): 549-54.
26. Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol. 2003; 112(4 suppl): S69-77.
27. Nathan RA, Mason J, Bernstein DI et al. Long-term tolerability of fexofenadine in healthy volunteers. Clin Drug Investig. 1999; 18(4): 317-28.
28. Church MK, Church DS. Pharmacology of antihistamines. Indian J Dermatol. 2013; 58(3): 219-24.
29. Hu Y, Sieck DE, Hsu WH. Why are second-generation H1-antihistamines minimally sedating? Eur J Pharmacol. 2015; 765: 100-6.